SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-127665
Filing Date
2022-04-28
Accepted
2022-04-28 16:25:34
Documents
12
Period of Report
2022-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A d216794ddef14a.htm DEF 14A 851224
2 GRAPHIC g216794g00a00.jpg GRAPHIC 176892
3 GRAPHIC g216794g00a01.jpg GRAPHIC 138556
4 GRAPHIC g216794g00a04.jpg GRAPHIC 112419
5 GRAPHIC g216794g00b02.jpg GRAPHIC 55168
6 GRAPHIC g216794g00b03.jpg GRAPHIC 49299
7 GRAPHIC g216794g00g01.jpg GRAPHIC 78166
8 GRAPHIC g216794g00g02.jpg GRAPHIC 50049
9 GRAPHIC g216794g00g03.jpg GRAPHIC 17164
10 GRAPHIC g216794g00g04.jpg GRAPHIC 45600
11 GRAPHIC g216794g00g05.jpg GRAPHIC 47397
12 GRAPHIC g216794g00u26.jpg GRAPHIC 29827
  Complete submission text file 0001193125-22-127665.txt   1953270
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36544 | Film No.: 22867059
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences